RLYB vs ARQT vs REGN vs AMGN

For growth investors, Arcutis Biotherapeutics, Inc.

(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 1x trailing P/E (15. 3x forward), making it the more compelling value choice. Analysts rate Rallybio Corporation (RLYB) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 17. 1x versus Amgen Inc. at 23. 1x. On forward P/E, Amgen Inc. is actually cheaper at 14. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Regeneron Pharmaceuticals, Inc. wins at 2. 43x versus Amgen Inc. 's 5. 01x.

Over the past 5 years, Amgen Inc.

(AMGN) delivered a total return of +46. 2%, compared to -87. 0% for Rallybio Corporation (RLYB). Over 10 years, the gap is even starker: AMGN returned +156. 4% versus RLYB's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amgen Inc.

(AMGN) is the lower-risk stock at 0. 60β versus Arcutis Biotherapeutics, Inc. 's 1. 48β — meaning ARQT is approximately 146% more volatile than AMGN relative to the S&P 500. On balance sheet safety, Rallybio Corporation (RLYB) carries a lower debt/equity ratio of 0% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.

(ARQT) is pulling ahead at 91. 3% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc. grew EPS 88. 8% year-over-year, compared to 8. 2% for Regeneron Pharmaceuticals, Inc.. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -90. 8% for Rallybio Corporation — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMGN leads at 29. 1% versus -95. 1% for RLYB. At the gross margin level — before operating expenses — RLYB leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Regeneron Pharmaceuticals, Inc. (REGN) is the more undervalued stock at a PEG of 2. 43x versus Amgen Inc. 's 5. 01x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Amgen Inc. (AMGN) trades at 14. 7x forward P/E versus 77. 6x for Arcutis Biotherapeutics, Inc. — 62. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARQT: 71. 8% to $35. 50.

In this comparison, AMGN (2.

9% yield), REGN (0. 5% yield) pay a dividend. RLYB, ARQT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Amgen Inc.

(AMGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 60), 2. 9% yield, +156. 4% 10Y return). Both have compounded well over 10 years (AMGN: +156. 4%, ARQT: -5. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RLYB is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock; REGN is a mid-cap deep-value stock; AMGN is a mid-cap quality compounder stock. AMGN pays a dividend while RLYB, ARQT, REGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.